AstraZeneca’s Zook to head global marketing

Share this article:
AstraZeneca US president and CEO Tony Zook will also lead the company’s global marketing efforts beginning next month. Zook will assume the additional role beginning May 1, AstraZeneca spokeswoman Laura King told MM&M. Zook takes over for Martin Nicklasson, currently EVP of global marketing for AstraZeneca and CEO of the company’s Swedish affiliate. Nicklasson has joined Swedish biotech Biovitrum as president and CEO. King told MM&M that Nicklasson’s departure and Zook’s new responsibilities have “absolutely nothing” to do questions raised on industry blogs about the AstraZeneca’s sales and marketing practices or the firing of a sales manager at its Wayne, PA office for comments he made in a company newsletter likening physicians to a “big bucket of money.” Biovitrum announced Nicklasson’s hiring in a news release on April 11. Nicklasson replaces Mats Pettersson, who departs Biovitrum after six years as CEO. Nicklasson will take up his new position on May 14. King added that right now “there is no indication” that Zook’s new role won’t be permanent, however no new title has been determined for him.
Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...